<DOC>
	<DOC>NCT00812071</DOC>
	<brief_summary>Dose escalation study: 3 dose groups. 5 patients in each dose group, then 15 more patients in "best" group. 3 vaccinations in volunteers, at 0 6 and 16 weeks.</brief_summary>
	<brief_title>Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin</brief_title>
	<detailed_description>Final report was submitted to Dr. Karen Russell at FDA, Rockville on September 26, 2012.</detailed_description>
	<criteria>healthy volunteers aged 1831, m or f immunodeficiency pregnant chronic disease parental IgG abnormal labs drug use hiv hep c hep b</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>31 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>volunteers</keyword>
</DOC>